foxo4-dri senolytic peptide human trial 2024 2025

foxo4-dri senolytic peptide human trial 2024 2025 The disordered p53 transactivation domain is the target of FOXO4 and the compound Molecular modelling of the FOXO4-TP53

Name: foxo4-dri senolytic peptide human trial 2024 2025 The disordered p53 transactivation domain is the target of FOXO4 and the compound Molecular modelling of the FOXO4-TP53
Brand: wiensworld.de
SKU: 27632742780
Price: 24.98 USD
Availability: InStock
Rating: 4.854100000000001 (24 reviews)

Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics (PDF) Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026)

SKU: 27632742780 · From wiensworld.de

4.9

USD24.98 USD46.98

Pay in 4 interest-free payments of $6.25 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 30 - Aug 4

Description

FOXO4-DRI 10MG $276.00 $200+ orders Discount per Quantity Scientific Overview of FOXO4-DRI FOXO4-DRI is a synthetic peptide derived from the FOXO4 protein, designed with retro-inverso (D-amino acid) substitutions